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Introduction
A 44 year-old-man was referred for cardiac catheterization because of symptoms of worsening exertional chest pain. The patient had required multiple percutaneous interventions in the past. Aside from his coronary history, the patient had been treated for diabetes mellitus, hypertension and hyperlipidemia. His medications included aspirin 81 mg daily, clopidogrel 75 mg daily, gemfibrozil 600 mg twice daily, simvastatin 80 mg daily, amlodipine 5 mg daily, carvedilol 25 mg twice daily, lisinopril 40 mg daily, isosorbide mononitrate 30 mg daily, and insulin. He denied any prior history of arrhythmia, dizziness, palpitations or syncope. His pre-catheterization electrocardiogram revealed normal sinus rhythm (SR) with a normal QT interval, and echocardiography demonstrated normal ejection fraction with apical septal hypokinesis.
Prior to coronary angiography, blood pressure (BP) was 126/61 mm Hg and heart rate was 81 bpm. Telemetry demonstrated normal SR. Angiography revealed progression of his underlying coronary disease, with multiple non-obstructive lesions. The most severe lesion was seen in the proximal posterior descending coronary artery (PDA), visually estimated at 60-70% stenosis. Given his clinical presentation of exertional angina, and the intermediate nature of the stenosis, the decision was made to pursue additional functional testing with fractional flow reserve (FFR).
FFR measurement was performed with a Volcano 0.014" pressure wire (PrimeWire™, Volcano Corporation, Rancho Cordova, CA, USA). During his FFR assessment, 70 µg of intra-coronary adenosine was administered. The patient initially developed transient third degree atrioventricular (AV) block during adenosine administration, and following resolution of the AV block, spontaneously developed atrial fibrillation (AF) with rapid ventricular response following a series of premature atrial contractions (PACs) (Fig. 1) The FFR measurement was 0.73, a clinically significant value, and the patient subsequently received a drug eluting stent to his PDA. The patient remained asymptomatic and hemodynamically stable with a BP of 113/69 and a pulse of 112 bpm. He did, however, remain in AF, and the decision was made to admit the patient to the telemetry floor for further monitoring and management of his arrhythmia. Intravenous amiodarone, Eugene Park et al., FFR and atrial fibrillation www.cardiologyjournal.org 150 mg bolus was administered, followed by a continuous infusion, with a plan to perform electrical cardioversion the following morning should he remain in AF. Aspirin, 325 mg orally, clopidogrel 75 mg orally, as well as his home dose of carvedilol 25 mg twice daily were administered. The patient successfully converted to SR by the following morning, and was discharged home on full dose aspirin, clopidogrel, and the remainder of his home medications.
Discussion
To the best of our knowledge, this is the first reported case of AF associated with adenosine infusion during FFR assessment. There is already a vast body of literature supporting the usefulness of FFR in the assessment of intermediate lesions, as well as the improved clinical outcomes associated with its usage [1] . The expectation is that FFR and adenosine administration during coronary angiography will become more widespread as a result of this evidence. To date, there is already a well-established link between adenosine and its ability to stimulate cardiac arrhythmias [2] . Adenosine infusion used for the diagnosis of coronary disease has confirmed this association, with AF induction following adenosine myocardial perfusion stress testing having been described previously [3] . The mechanism of this association has been attributed to adenosine's ability both to decrease atrial refractory periods as well as to shorten the action potential duration, making the atrial myocardium more susceptible to arrhythmia induction [2, 4] . In addition, evidence also links adenosine administration to the induction of PACs, which has been clearly linked to the induction of AF [2] .
Currently, there is no reported incidence of this complication related to FFR assessment; however, the morbidity associated with AF makes this an important side effect to consider during functional assessment of intermediate coronary lesions. It is uncertain whether this complication may be more frequently encountered with intracoronary or intravenous adenosine administration. Additionally, the impact of the dose of intracoronary adenosine, administration to the left or right coronary system, coronary dominance or amount of ischemic myocardium on the induction of AF is unknown.
Conclusions
This case represents a well-described side effect related to adenosine infusion, albeit in a unique setting of FFR assessment. With the growing frequency of FFR assessment during coronary angiography, although rare, the initiation of AF with intracoronary adenosine may be increasingly encountered. 
